Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing
PR88781
WETTEREN, Belgium, March 31, 2021 /PRNewswire=KYODO JBN/ --
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of
biopharmaceutical contract development and manufacturing services, is pleased
to announce a manufacturing agreement expansion with AstraZeneca to include
drug product manufacturing.
Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg
This agreement expands the scope of Aji Bio-Pharma's service offerings to
AstraZeneca to include aseptic fill finish services at its San Diego,
California facility, in addition to small molecule manufacturing services
proceeding in Belgium.
"We are excited to expand our manufacturing agreement with AstraZeneca and to
support them with additional service offerings," said Magnus Busch, Global
Account Manager, Ajinomoto Bio-Pharma Services. "Our San Diego team is proud to
join our Belgium colleagues in support of AstraZeneca. This expanded agreement
builds on our commitment to be a leading, trusted, innovative partner to our
clients."
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and
manufacturing organization with sites in Belgium, United States, Japan, and
India, providing comprehensive development, cGMP manufacturing, and aseptic
fill finish services for small and large molecule APIs and intermediates.
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and
capabilities for pre-clinical and pilot programs to commercial quantities,
including Corynex(R) protein expression technology, oligonucleotide synthesis,
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is
dedicated to providing a high level of quality and service to meet our client's
needs. Learn more: www.AjiBio-Pharma.com
SOURCE Ajinomoto Bio-Pharma Services
CONTACT: Ajinomoto Contact: info@us.ajibio-pharma.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。